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Objective: To investigate the possible role and tolerability of high-dose (160 mg/day) 
oxycodone controlled release (CR) for the treatment of cancer and non-cancer pain.
Design: 227 patients with cancer or non-cancer pain were enrolled in an open-label, multi-center, 
Italian study in order to assess the adequacy of their existing pain management (using a numerical 
rating scale [NRS]) and the possible beneﬁ  t high-dose oxycodone CR may offer patients 
experiencing uncontrolled pain.
Results: Pain was poorly controlled at baseline, with only 18.1% of patients reporting adequate 
pain relief (NRS 3.5). All other patients reported uncontrolled pain, with an average NRS of 
7.81. At baseline assessment, 47.89% of patients had been in pain for up to 3 months, 32.82% 
for 3–6 months, and 19.19% for more than 6 months. After baseline assessment, patients were 
switched to oxycodone CR monotherapy. The starting dose was individualized to each patient 
and titrated up over a 3- to 4-day period until effective pain management was achieved. Treatment 
was continued for an average of 37.24 days during the study. Pain control (ﬁ  nal mean NRS of 
2.85) was attained with an average dose of oxycodone CR 221.84 mg/day. Standard adverse 
events (including constipations, nausea, and vomiting) were recorded in 39.64% of patients 
receiving high-dose oxycodone CR monotherapy. Side-effects tended to subside after the initial 
week of treatment and did not result in any participants leaving the study.
Conclusion: High-dose oxycodone CR can achieve rapid and effective management of moderate 
to severe cancer and non-cancer pain with minimum side-effects.
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Introduction
Living with pain is a reality that affects millions of people worldwide. Cancer pain 
alone is a signiﬁ  cant issue, affecting an estimated 17 million people every year (Goudas 
et al 2005). Evidence suggests that around 70% of patients living with cancer have to 
endure chronic pain: 70% of which is caused by the disease, 20% by therapy, and 10% 
by other factors (Italian Department of Health 2007). Non-cancer-related pain also 
affects a signiﬁ  cant number of people worldwide (Furlan et al 2006) and is thought to 
affect over a third of the population in developed countries. Data from the International 
Association for the Study of Pain (IASP) indicate that chronic pain is more common 
among women, affecting 39.6% of women compared with a prevalence of 31.0% 
among men (Yang et al 2007).
It has been shown on a pan-European level that, in addition to its impact on the 
quality of life (QoL) of affected individuals and their families, chronic pain also has 
a signiﬁ  cant social and economic burden. Persistent pain can affect a patient’s ability 
to perform simple tasks which, combined with a lack of availability of treatments 
and effective therapies, can undermine their ability to work. This is not only valid 
at a European level, but also holds true on a national scale. In Italy, 83.2% of 
cancer patients were found to be in pain as a result of their condition, and, although Therapeutics and Clinical Risk Management 2008:4(4) 666
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97% of them were receiving therapy, the treatment was not 
appropriately tailored to relieve the intensity of pain experi-
enced (Costantini et al 2005).
Pain is often the main presenting symptom when patients 
visit their primary care physician. The location and nature 
of the pain can inform doctors on the cause and possible 
pathology of a patient’s condition. In Italy, however, diag-
nosis and subsequent treatment choice are often inadequate, 
with a signiﬁ  cant 42% of cancer patients describing their pain 
as ‘intolerable’ despite treatment (Italian Medical Oncology 
Association 2007).
The European Pain in Cancer (EPIC) Survey ﬁ  ndings 
provided further insight into the nature and prevalence of 
cancer pain at presentation (European Pain in Cancer Survey 
2007). The survey encompassed 12 European countries and 
involved a total of 4824 patients, of whom 457 were Italian. 
Across Europe 73% of patients reported pain associated with 
their cancer, with approximately one in three (33%) identify-
ing it as the main symptom of their condition. This number 
was higher for Italy, where almost all Italian participants 
(95%) reported pain associated with their cancer, and 42% 
identiﬁ  ed pain as their key symptom.
More than half (56%) of patients reported pain at the 
time of questioning, while 96% of patients in the survey 
experienced pain at least once a month, and 75% weekly. 
At the time of the survey, nearly 47% of patients had been 
suffering pain for at least 3 months, and 6% reported having 
been in constant pain for more than a year.
Patients were asked to indicate the severity of their 
pain on a numerical rating scale (NRS) that ran from 1 to 
10, with 10 indicating the worst pain possible. More than 
96% of patients classiﬁ  ed their pain as moderate-to-severe, 
with an NRS of 5. Although 98% of patients involved in 
the study had received some form of pain treatment, only 
24% of pan-European participants considered their treat-
ment effective. This number was even lower for the Italian 
participants, among whom only 16% felt their treatment 
was effective. A signiﬁ  cant 70% of patients involved in 
the study reported a belief that effective pharmacological 
pain control was not possible (European Pain in Cancer 
Survey 2007).
Poor pain control, as recorded in the study, contributes to 
the psychosocial and physical effects associated with chronic 
pain. In addition to the physical sensation of pain, patients can 
also experience sleep disturbance, fear, anxiety, depression, 
weight loss, reduced physical activity, social isolation, and 
problems with social interaction that often result in problems 
ﬁ  nding and maintaining employment. Chronic pain’s high 
prevalence and debilitating nature result in a signiﬁ  cant 
combined economic and social burden.
The impact of chronic pain on the patient, society, and 
the economy highlights the need to focus on, and address, 
pain on both a national and international scale. Recognition 
of the importance of ﬁ  nding an efﬁ  cacious approach to pain 
management leads to arguments supporting the extensive use 
of opioids in chronic pain management (Ballantyne 2007). 
Opioids are considered by some to be integral to effective pain 
management, and key to minimizing the suffering associated 
with persistent pain (European Pain in Cancer Survey 2007), 
its deleterious physical effects (Carr et al 1999; Kehlet et al 
2003; American Academy of Pain Medicine Council on Ethics 
2005), and its erosion of a patient’s autonomy, dignity, and 
decision-making capacity. However, the potentially addictive 
nature of opioids is also recognized, and caution is advised to 
ensure that the ‘principle of balance’ is upheld. The principle 
of balance maintains that efforts to address abuse of therapy 
may be necessary, but they should not interfere with legitimate 
medical practice and patient care (Brennen et al 2005; Dubois 
2005). Furthermore, long-term studies into the use of opioids 
have not only found that prolonged treatment can improve 
patients’ functioning and QoL, but also that it is possible to 
reach, and maintain, a stable (non-escalating) effective dose. 
The established side-effects associated with opioid use, such as 
nausea, sedation, constipation, and itching, also tend to subside 
with prolonged use, as side-effect tolerance appears to develop 
without an associated abrogation of analgesic effect.
The opioid oxycodone controlled release (CR) is com-
monly used for pain relief in cancer patients, and may be 
considered for ﬁ  rst-line oral therapy. In a study on visceral 
pain, Staahl et al (2007) demonstrated that oxycodone 
CR has superior analgesia to morphine. In addition, the 
European Federation of Neurological Societies’ (EFNS) 
recently recommended use of oxycodone alone for the treat-
ment of painful polyneuropathy (PPN) at a level rating of A 
(that requiring the existence of a strong evidence base) (Attal 
et al 2006). A recent study investigating the efﬁ  cacy and tol-
erability of high-dose oxycodone CR achieved optimum pain 
control at a dosage of oxycodone CR 224 mg/day; resulting 
in a signiﬁ  cant reduction in pain intensity (ﬁ  nal NRS 3) 
with a favorable side-effect proﬁ  le (Mameli et al 2006).
Yet, published evidence on the use of high-dose oxyco-
done CR in patients with terminal cancer remains limited 
(Bercovitch et al 2006). This study sought to address the 
gap in the evidence base by assessing the possible role and 
tolerability of high-dose (160 mg/day) oxycodone CR in 
the management of cancer and non-cancer pain.Therapeutics and Clinical Risk Management 2008:4(4) 667
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Methods
The study was designed as an open-label, multi-center, obser-
vational trial carried out across 10 locations. It ran for 3 months 
(from 1 April to 30 June 2007) and involved a total of 227 con-
secutive patients: 207 patients with cancer pain and 20 patients 
with non-cancer pain. A baseline pain evaluation was carried out 
using a NRS, and previous treatments were recorded to establish 
the most commonly prescribed therapy, and then correlated 
against the patient’s perception of treatment efﬁ  cacy.
The goal of the study was to reduce the intensity of 
pain experienced by participants. The study sought to 
establish whether prescription of an appropriate therapy, as 
recommended by the World Health Organization’s (WHO) 
guiding principles: ‘by the clock, by the mouth, by the ladder’, 
could improve patients’ pain relief (WHO 1996).
Patients included in the study were over 18 years of age, 
had a baseline NRS score of 4 and were able to take oral 
medication. Patients were excluded from the study if they 
were undergoing current radiotherapy treatment, required 
modiﬁ  cation of adjuvant treatments, or were known to be 
intolerant to oxycodone.
Baseline assessments included cause of pain, duration 
of pain experienced prior to study, history of pain relief pre-
scribed, treatment setting, and intensity of pain felt (indicative 
of treatment efﬁ  cacy) using a NRS. After baseline assessment, 
patients were switched to oxycodone CR monotherapy and 
monitored for at least 21 days. The change in therapy followed 
recommendations outlined in Doyle et al (1997). Existing 
therapy was halted completely as study patients reported 
uncontrolled pain on current treatment (NRS 4) and were 
then switched to oxycodone CR. After the change from 
previous treatment to oxycodone CR, patients’ pain score was 
evaluated and the high-dose oxycodone CR dosage was titrated 
up until adequate control (NRS 2.9) was achieved.
Duration of therapy varied depending on date of enrolment 
in the study, but high-dose oxycodone monotherapy was 
taken by study participants for an average of 37.24 days. 
Oxycodone CR was chosen as the reference drug because of 
its pharmacokinetics, pharmacodynamics, and demonstrable 
efﬁ  cacy in both cancer and non-cancer pain. The setting for 
treatment administration was not altered for the study. Initial 
dose was individualized to each patient, using standard 
conversion tables (Doyle et al 1997) and consideration of 
pharmacological history (previous treatment and dosage used), 
and titrated up (over a 3- to 4-day period) until effective pain 
control was achieved.
Results
During the 3-month study period, 227 patients from 10 sites 
were evaluated. The patient population comprised 40% 
women (n = 90) and 60% male (n = 137). Patients were 
aged 27–84 years (average 63.76 years). Within the 91.18% 
(n = 207) of patients with cancer, the following categories 
were deﬁ  ned: 23.34% (n = 53) lung; 13.21% (n = 30) breast; 
10.13% (n = 23) prostate; 9.25% (n = 21) pancreas; and 
6.16% (n = 14) colon (Figure 1; Table 1).
Study participants were administered treatment in a 
number of different settings: outpatient (n = 88); in the home 
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Figure 1 Cause of pain among study participants at baseline.Therapeutics and Clinical Risk Management 2008:4(4) 668
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(n = 64); hospice (n = 33); secondary care hospital (n = 24); 
day hospital (n = 17); and residential service agency (n = 1) 
(see Figure 2).
Of the 198 participants who responded to questioning at 
baseline, 47.98% (n = 95) had been in pain for 3 months, 
32.83% (n = 65) for 3–6 months, and 19.19% (n = 38) for 6 
months (Figure 3).
Evaluation of pain intensity was also assessed at study 
outset. The overall NRS calculated for participants at the 
outset of the study was 7.73, indicating that pain was uncon-
trolled among most patients. Baseline analysis reported 
controlled pain (deﬁ  ned as NRS 2.9, p  0.00001) in 8.1% 
(n = 41) of patients, all of whom were receiving high-dose 
oxycodone CR (an average dose of 241 mg/day). All other 
patients reported uncontrolled pain, with an average NRS 
of 7.81. Of note, 3.96% (n = 9) recorded an NRS of 5, 
while a signiﬁ  cant 24.67% (n = 56) indicated a NRS of 8, 
and 10.13% (n = 23) recorded a maximum 10 on the NRS 
(Figure 4; Table 2).
A range of pharmacological agents were in use among 
patients who reported uncontrolled pain (Figure 5): 
transdermal fentanyl (30.0%); morphine (12.8%); transdermal 
buprenorphine (5.3%); weak opioids (6.2%); and non-steroidal 
anti-inﬂ  ammatory drugs (NSAIDs) (1.3%). Of patients who 
reported poor pain control, 42.2% were treated with low-dose 
(80 mg/day) oxycodone (either oxycodone/acetaminophen 
or oxycodone CR). Analysis found that breakthrough pain 
had been treated with immediate-release morphine (33.02%), 
transmucosal fentanyl (24.18%), NSAIDs (12.09%), immedi-
ate-release oxycodone (in the form of oxycodone/acetamino-
phen) (4.65%), and weak opioids (0.9%).
During the study, all patients experiencing uncontrolled 
pain were switched from their original treatment to oxyco-
done CR monotherapy. The initial dose administered was 
titrated up until effective pain relief was achieved. Pain 
control (NRS  2.9) was attained using an average dose of 
oxycodone CR 221.84 mg/day, resulting in an average NRS 
of  2.85 at study end (p  0.00001). All patients on oxycodone 
CR in the study were treated for an average treatment duration 
of 37.24 days. Side-effects (including constipation, nausea, 
and vomiting) were recorded among 39.64% of patients on 
high-dose oxycodone CR monotherapy, but tended to subside 
14.5%
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Figure 2 Setting for treatment administration.
Table 1 Summary of patient demographics at baseline (n = 227)
Sex Female Male
90 (40%) 137 (60%)
Age Range (years) Average (years)
27–84 63.76
Cancer pain lung breast prostate pancreas colon
207 (91.18%) 53 (23.34%) 30 (13.21%) 23 (10.13%) 21 (9.25%) 14 (6.16%)Therapeutics and Clinical Risk Management 2008:4(4) 669
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after the ﬁ  rst week of treatment and did not result in any 
patients leaving the study (Table 3).
Discussion
This study corroborates the poor management of both 
cancer and non-cancer pain in Italian patients. In a signiﬁ  -
cant number of cases the wrong therapeutic approach was 
taken: transdermal treatments were used over oral agents for 
ﬁ  rst-line therapy in more than a third of patients (35.3%), 
despite no prior stabilization of their pain. In addition, the 
dose prescribed was not optimized in a large number of cases, 
as highlighted by the use of low-dose oxycodone in 42.2% 
of patients who reported persistent pain despite treatment. 
The study demonstrates that oxycodone CR can be used in 
such patients to achieve rapid control of moderate to severe 
pain, with minimal side-effects.
Although the mean duration of therapy in this trial was 
only 37.24 days, a separate study carried out over a 3-year 
period demonstrated that oxycodone CR can achieve 
adequate, longer-term pain management of non-cancer 
pain, without requiring a further increase in dose (Portenoy 
et al 2007).
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Figure 3 Duration of uncontrolled pain (in 3-month periods) among study participants at baseline.
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Figure 4 Pain severity as classiﬁ  ed by study participants at baseline using numerical rating scale (NRS).Therapeutics and Clinical Risk Management 2008:4(4) 670
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Figure 5 Distribution of pharmacological therapy that failed to achieve pain control at baseline.
Pain is one of the most common symptoms associ-
ated with cancer. It becomes more frequent as the cancer 
progresses, but may also be present during the early stages 
of the disease. Pain associated with cancer is largely due to 
the condition itself, but can (in 20% of cases) be caused by 
treatment complications.
An overlap in pain caused by antineoplastic treatments 
and that caused by cancer was recorded in around 10% of 
patients in a recent study (n = 1095) by Caraceni et al (1999). 
Sources of cancer pain in the study were classiﬁ  ed as bone 
lesion (due to metastases or to tumor invasion of bone and 
joint structures) in 41% of patients, neoplastic visceral dam-
age in 28%, and lesions of the nervous system in 28% of 
cases. These were further classiﬁ  ed into the following pain 
pathophysiologies: somatic, visceral, and neuropathic. The 
most common pathophysiology was somatic-nociceptive 
pain (32.0%), followed by somatic-neuropathic (23.0%), 
pure visceral pain (15.0%), pure neuropathic pain (7. 7%), 
and other syndromes of mixed pathophysiologies.
The aim of treatment in patients with advanced-stage 
cancer is improved QoL, which requires both efﬁ  cacious treat-
ment and adequate pain relief. Clinical experience conﬁ  rms 
that optimal palliative care in cancer is associated with maxi-
mal pain relief. Yet, despite international guidelines on cancer-
pain management (WHO 1996) and availability of treatments 
that are effective in approximately 70%–90% of cases, up to 
40% of cancer patients in Italy remain under-treated.
The European Society for Medical Oncology (ESMO) 
advocates the use of opioids as first-line therapy in 
moderate to severe cancer pain (ESMO Guidelines Task 
Force 2005, 2007). Guidance suggests that strong opioids 
can be safely administered, in increasing amounts, until pain 
relief is achieved. No ceiling dose is outlined, and no standard 
initial dose is suggested; the correct dose is one that achieves 
effective pain relief, and may vary among patients. The WHO 
recommends that pharmacological pain management should 
be guided by the core principles of: ‘by the mouth, by the 
clock, by the ladder’ (WHO 1996). ‘By mouth’ embodies the 
recommendation of oral therapy use (where possible) as it can 
be rapidly modiﬁ  ed to changing intensities of pain. Transder-
mal formulations are recommended only in patients in whom 
pain management is stable, not as ﬁ  rst-line therapy.
Oxycodone is derived from thebaine, an opium alkaloid. 
It is a semi-synthetic, pure opioid receptor agonist analgesic 
drug that appears to work by stimulating the μ-opioid recep-
tors found in the central nervous system (Glare et al 1993; 
Reder et al 1993; Citron et al 1998; Napp Pharmaceuticals 
2007). Oxycodone is metabolized by the liver (by the cyto-
chrome P450 2D6) to form oxymorphone and noroxycodone, 
which has only weak afﬁ  nity for μ-opioid receptors. Despite 
it being a potent analgesic, oxymorphone accounts for only 
10% of oxycodone metabolites. Oxycodone, rather than 
Table 2 Summary of pain control at baseline (n = 198)
Average NRS score 7.73
NRS 2.9 (controlled pain) 41 (8.1%)
NRS 5 (uncontrolled pain) 9 (3.96%)
NRS 8 (uncontrolled pain) 56 (24.67%)
NRS 10 (uncontrolled pain) 23 (10.13%)Therapeutics and Clinical Risk Management 2008:4(4) 671
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oxymorphone, appears to be responsible for both analgesia 
and side-effects. Recent studies have demonstrated a role for 
oxycodone as ﬁ  rst-line pain therapy in place of morphine 
(Riley et al 2006), and evidence for its use, in both cancer 
and non-cancer pain, is growing.
Conclusion
Oxycodone CR is an oral therapeutic option approved for the 
treatment of moderate to severe pain. It has a similar safety 
and efﬁ  cacy proﬁ  le to morphine, but offers several therapeutic 
advantages. The results of its use at high dosages for pain relief 
in cancer and non-cancer patients demonstrate that an adequate 
dose can bring previously uncontrolled moderate to severe pain 
under control rapidly, with minimal side-effects. However, 
further randomized, controlled studies involving oxycodone 
CR and a control arm are required to increase evidence for the 
efﬁ  cacy of oxycodone CR use in cancer and non-cancer pain.
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